Jinsy A. Andrews, MD, a specialist in neuromuscular medicine and amyotrophic lateral sclerosis (ALS), has joined NYU Langone Health’s Department of Neurology to lead its new ALS Center. The center aims to advance ALS treatments through research, provide integrated care for patients, and work toward finding a cure.
Dr. Andrews has focused her career on understanding ALS and improving patient care. She previously served as co-chair and scientific advisory board member of the Northeast ALS Consortium, where she worked to apply new discoveries in the field to clinical practice. At NYU Langone, she will oversee individualized care that includes rehabilitation and pulmonary services.
“Dr. Andrews is a pioneer in her field and brings an incredible wealth of knowledge on what needs ALS patients have and how our integrated health system can best serve them,” said Steven L. Galetta, MD, chair of neurology at NYU Grossman School of Medicine. “She will lead one of the most comprehensive ALS programs in the region.”
According to Dr. Andrews, the new center will combine clinical practice with research, social work, genetic counseling, rehabilitation, and dedicated nursing support for patients. She emphasized the importance of early diagnosis, access to clinical trials for innovative treatments, and using technology to monitor symptoms such as respiratory health.
“I am excited to bring together a multidisciplinary team that will deliver the integrated, seamless service that ALS patients deserve,” Dr. Andrews said. “Combined with access to the latest experimental medicines and innovative treatments, NYU Langone is poised to provide ALS patients with the best possible care available—and one day, a cure.”
Dr. Andrews completed her education at Union College and Albany Medical College before training in neurology at the University of Connecticut and pursuing fellowships at Columbia University Medical Center in both neuromuscular disease and clinical neurophysiology.
Before joining NYU Langone Health, Dr. Andrews was associate professor of neurology at Columbia University’s Vagelos College of Physicians and Surgeons as well as director of neuromuscular clinical trials at Columbia University Irving Medical Center. Her previous roles include senior director at Cytokinetics Inc., co-director at Muscular Dystrophy Association/ALS clinic in Connecticut, and director of research at Hospital for Special Care.
She was nominated for the 2024 Sheila Essay Research Award by the American Academy of Neurology for her contributions to ALS research and received the International Prize for Innovation from the International Symposium on ALS/MND in 2022.
Currently serving as co-principal investigator for ALL ALS—a nationwide NIH-funded study—Dr. Andrews collaborates with other institutions on natural history studies and biomarker development related to ALS. She has led several multimillion-dollar NIH-funded projects involving experimental medications and technology applications while publishing over 60 peer-reviewed articles.
NYU Langone Health operates as an integrated health system known for high patient outcomes due to its focus on quality care standards across multiple locations including inpatient hospitals in New York area and Florida; it also features two tuition-free medical schools located in Manhattan and Long Island.
